Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNELARABINE (nelarabine) by Gland Pharma is nucleic acid synthesis inhibitors [moa]. Approved for t-cell lymphoblastic lymphoma (t-lbl) in adult, older whose disease has not responded to, leukemia and 1 more indications. First approved in 2024.
Drug data last refreshed 20h ago
Nucleic Acid Synthesis Inhibitors
Nucleoside Metabolic Inhibitor
Worked on NELARABINE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Observational Study of Nelarabine in Children and Young Adults
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo